The NeurologyLive® Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.
October 28th 2024
As part of our monthly clinician spotlight, NeurologyLive® highlighted movement disorder expert Sana Aslam, DO, an assistant professor of neurology at University of Colorado School of Medicine.
Extended-Release Amantadine Shows Reduction in Dyskinesia Severity for Parkinson Disease
October 1st 2024Amantadine extended-release capsules, approved for levodopa-related dyskinesia and OFF episodes in Parkinson disease, offer high amantadine concentrations that peak in the time of first morning levodopa dose.
Randomized Controlled ELATE Study to Test OnabotulinumtoxinA in Upper Limb Essential Tremor
September 30th 2024ELATE, a multicenter, randomized, double-blind, placebo-controlled trial, aims to address the limitations of current oral therapies by exploring a targeted, localized treatment option.
Nocturnal and Morning Akinesia Still Prevalent After Nighttime Add-On Parkinson Medications
September 30th 2024In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.
Significance of Medtronic’s DBS System Approved for Asleep Neurosurgery
September 8th 2024Ashwini Sharan, MD, chief medical officer of Medtronic Neuromodulation, provided commentary on the FDA’s decision to approve asleep deep brain stimulation for the treatment of Parkinson disease and essential tremor.
FDA Approves Carbidopa/Levodopa ER Capsules Formulation IPX203 for Parkinson Disease
Published: August 7th 2024 | Updated: August 8th 2024Marketed as Crexont, the combination extended- and immediate-release treatment is indicated for treatment of PD, and is anticipated to be available in the United States in September 2024.
Transforming the Landscape of Parkinson Disease Care Through Patient-Centric Focus
July 26th 2024Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.
Advances in Therapeutic Management for Parkinson Disease and Essential Tremor
July 25th 2024Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.
New FNIH Initiative Looks to Expedite Parkinson Disease Diagnosis Through Validated Biomarkers
July 23rd 2024Steve Hoffmann, MS, and Alessio Travaglia, PhD, provide commentary on a recently launched public-private partnership aimed at identifying biomarkers to better differentiate Parkinson disease from other related neurodegenerative disorders.
A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease
Published: July 22nd 2024 | Updated: July 24th 2024Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.
Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study
July 3rd 2024Over the 3-year treatment period, buntanetap resulted in improvements in motor and nonmotor functions in patients with postural instability and gait difficulty, a group with faster disease progression.
Cleveland Clinic's Parkinson Disease Inpatient Program Improves Patient Outcomes
June 28th 2024The Cleveland Clinic Foundation Parkinson's Inpatient Program is a proactive, multidisciplinary intervention aimed to enhance the quality and safety of care for hospitalized patients with Parkinson disease.
Advancements in Multidisciplinary Parkinson Disease Treatment: Michael Soileau, MD, FAAN
June 26th 2024The movement disorder specialist at Texas Movement Disorder Specialists talked about a comprehensive panel discussion that highlighted the evolution of Parkinson disease treatment. [WATCH TIME: 4 minutes]